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High mobility group box 1 (HMGB1) is a non-histone protein which is predominantly
localised in the cell nucleus. However, stressed, dying, injured or dead cells can release
this protein into the extracellular matrix passively. In addition, HMGB1 release was
observed in cancer and immune cells where this process can be triggered by various
endogenous as well as exogenous stimuli. Importantly, released HMGB1 acts as a so-
called “danger signal” and could impact on the ability of cancer cells to escape host
immune surveillance. However, the molecular mechanisms underlying the functional role
of HMGB1 in determining the capability of human cancer cells to evade immune attack
remain unclear. Here we report that the involvement of HMGB1 in anti-cancer immune
evasion is determined by Toll-like receptor (TLR) 4, which recognises HMGB1 as a ligand.
We found that HGMB1 induces TLR4-mediated production of transforming growth factor
beta type 1 (TGF-b), displaying autocrine/paracrine activities. TGF-b induces production
of the immunosuppressive protein galectin-9 in cancer cells. In TLR4-positive cancer cells,
HMGB1 triggers the formation of an autocrine loop which induces galectin-9 expression.
In malignant cells lacking TLR4, the same effect could be triggered by HMGB1 indirectly
through TLR4-expressing myeloid cells present in the tumour microenvironment (e. g.
tumour-associated macrophages).
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High mobility group box 1 (HMGB1) is a non-histone protein
predominantly localised in the cell nucleus where it promotes
nuclear transcription processes by interacting with DNA (1–4).
However, HMGB1 can be passively released into the extracellular
matrix by dead, dying or injured cells (1–4). It can also be
secreted by cancer and immune cells in response to various
exogenous or endogenous stimuli (1–4). Secreted HMGB1 acts
as a “danger signal” or “alarmin” which may also trigger
malignant tumour progression (1–4). We have recently
reported that HMGB1 promotes the generation and secretion
of interleukin-1beta (IL-1b), which induces production of stem
cell factor (SCF) by competent cells (5, 6). As such, it could
facilitate progression of malignancies such as acute myeloid
leukaemia (AML) (6–8).
HMGB1 was reported to act as a ligand for various immune
receptors including toll-like receptors (TLRs) 2 and 4, which
normally recognise pathogen-associated molecular patterns
shared by Gram-negative and Gram-positive bacteria
respectively (6). HMGB1 receptors also include receptor of
advanced glycation end products (RAGE) and the immune
receptor Tim-3 (T cell immunoglobulin and mucin domain
containing protein 3) (4, 6). Through these receptors HMGB1
in its immunogenic form could trigger both pro-inflammatory
and pro-angiogenic responses (6). Our recent work also
suggested that, in Toll-like receptor 4 (TLR4)-expressing
cells, HMGB1 induces the production and secretion of
transforming growth factor beta type 1 (TGF-b) (9). TGF-b
displays both autocrine and paracrine activities and, through
the transcription factor Smad3, induces expression of galectin-9,
an immunosuppressive protein which impairs the anti-cancer
activities of natural killer and cytotoxic T cells (9, 10). Galectin-9
is known as a so-called “tandem protein” which contains
two ligand/sugar-binding domains fused together by a linker
peptide. As a result of alternative splicing, galectin-9 may
be present in three main isoforms which differ because of
the length of their linker peptide: long (49 amino acids),
medium (27 amino acids) and short (15 amino acids) isoforms
(11–13).
Currently, the molecular mechanisms underlying the role of
the immunogenic form of HMGB1 in determining the capability
of human cancer cells to escape host immune surveillance
remain unclear. We hypothesised that HMGB1 could
upregulate galectin-9 expression in cancer cells through the
activation of TGF-b production induced in a TLR4-dependent
manner. Here we report for the first time that the role of HMGB1
in anti-cancer immune evasion is determined by the TLR4.
Cancer cells expressing TLR4 release TGF-b in response to
stimulation with HMGB1 followed by TGF-b-induced
upregulation of galectin-9 expression, forming such an
HMBG1-triggered autocrine loop. Galectin-9 expression in
cancer cells lacking functional TLR4 could still be triggered by
HMGB1 indirectly via induction of TGF-b expression in TLR4-
positive myeloid cells (e.g. tumour-associated macrophages)
present in the tumour microenvironment. Importantly, otherFrontiers in Immunology | www.frontiersin.org 2HMGB1 receptors did not demonstrate any involvement in the
process of induction of TGF-b expression by this danger signal
and its follow-up events.MATERIALS AND METHODS
Materials
RPMI-1640 medium for culturing the cells, foetal bovine serum,
supplements and basic laboratory chemicals were purchased
from Sigma (Suffolk, UK). Microtiter plates for ELISA were
obtained from Oxley Hughes Ltd (London, UK). Rabbit
antibodies against galectin-9, RAGE and phospho-S423/S425-
Smad3 as well as mouse antibodies against TLRs 2 and 4 were
purchased from Abcam (Cambridge, UK). Antibodies against b-
actin were purchased from Abcam (Cambridge, UK) and
Proteintech (Manchester, UK). Goat anti-mouse and anti-
rabbit fluorescently-labelled dye secondary antibodies were
obtained from Li-COR (Lincoln, Nebraska USA). ELISA-based
assay kits for the detection of galectin-9, Tim-3 and TGF-b as
well as human recombinant TGF-b1 protein were purchased
from Bio-Techne (R&D Systems, Abingdon, UK). ELISA kits for
the detection of HMGB1 were purchased from MyBioSource
(San Diego, CA. USA). Human HMGB1 and anti-Tim-3 mouse
monoclonal antibody were described before (6, 14). All other
chemicals purchased were of the highest grade of purity
commercially available.
Cell Lines and Primary Human Samples
Cell lines used in this work were purchased from either the
European Collection of Cell Cultures (THP-1, Colo-205 and
MCF-7) or the American Tissue Culture Collection (ATTC –
HEK293). Cell lines were accompanied by identification test
certificates and were grown according to corresponding tissue
culture collection protocols.
For description of primary cells (9, 15–17) please see the
Ethics statement.
Plasmids
Plasmid encoding constitutively active human TLR4 (murine
CD4 fused to human TLR4) (18) was generously provided by
Professor Medzhitov (Yale University, New Haven, USA).
Cell Transfection
mCD-hTLR4 expression plasmid or empty expression vector
were transfected into Colo 205 cells using DOTAP transfection
reagent according to the manufacturer’s protocol.
Western Blot Analysis
Galectin-9, Tim-3, phospho-S423/S425 Smad-3, RAGE, TLRs 2
and 4 were measured by Western blot and compared to the
amounts of b-actin (protein loading control), as previously
described (18).
Li-Cor goat secondary antibodies conjugated with infrared
fluorescent dyes, were used as described in the manufacturer’s
protocol in order to visualise specific proteins (Li-Cor OdysseyJune 2021 | Volume 12 | Article 675731
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quantitatively analysed using Odyssey software and values were




Secreted HMGB1, TGF-b, galectin-9 and Tim-3 were measured,
either in cell culture medium or in blood plasma (galectin-9 was
also measured in some of the cell lysates), by ELISA using
MyBioSource or R&D Systems kits (see Materials section)
according to manufacturer’s protocols.
Design of Nanocomplexes For
Immunoprecipitation Containing
Anti-HMGB1 and Anti-TGF-b Antibodies
Nanoconjugates (nanocomplexes) were designed using 30 nm gold
nanoparticles (AuNPs). The synthesis of 30 nm AuNPs was
performed essentially as described previously (16, 19). Briefly,
5 ml of aqueous gold (III) chloride trihydrate (10 mM) and
2.5 ml of aqueous sodium citrate (100 mM) were added to 95 ml
of MilliQ-water in a round bottom flask supplied with a magnetic
stirrer, and the resulting pale-yellow solution was allowed to cool to
1–2°C. Under vigorous stirring, 1 ml of chilled (4°C) aqueous 0.1 M
sodium borohydride was added and the dark red solution obtained
was then stirred for further 10 min in an ice bath before being
allowed to warm to room temperature. The obtained AuNPs were
characterised using transmission electron microscopy (TEM) as
previously described (16, 20). TEM image of the AuNP is presented
in the Supplementary Figure 1. Antibody molecules were attached
as described before in the ratio of 1 AuNP: 6 antibody molecules in
both cases. A sample scheme of the nanoconjugate and its action are
presented in Supplementary Figure 2. Briefly, the antibody
(biotinylated anti-HMGB1 or anti-TGF-b) was coupled to 30 nm
AuNPs using glutathione (GSH, tripeptide containing g-glutamate,
cysteine-SH and glycine) as a linker. A 0.05 M solution of GSH was
incubated for 2 h at room temperature with a 1 : 1 mixture of
aqueous solutions of 0.4 M 1-ethyl-3-(3-dimethylpropyl)-
carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide (NHS) to
allow the activation of GSH –COOH groups, thus enabling them to
interact with antibody amino groups. Activated GSH was then
mixed with an antibody in an equimolar ratio and incubated for at
least 2 h at 37°C. The antibody was then mixed with 30 nm AuNPs
(0.5 mM) at a ratio of 1 AuNP: 6 antibody molecules. This mixture
was incubated for at least 18 h at room temperature.
The available amount of AuNPs was calculated using the
following equations:
NAuNP = mtotalAu=mAuNP(m = mass;  N = quantity);
mtotalAu = CAu(mol  l−1)MWAu(g mol−1) VAuNP
(C = molar concentration,  MW = molecular weight,VAuNP
= the volume of  the AuNP suspensionused);Frontiers in Immunology | www.frontiersin.org 3m1 AuNP = rAu  V1 AuNP ; (r = density,  V = volume; rAu
= 19:3   g cm−3);
V1AuNP = 4=3 pR
3; (R = radius of  a AuNP)
R = d1AuNP=2; (d = diameter of 1 AuNP expressed in cm)
The amount of antibody molecules was calculated from the
molar weight of the antibodies (150,000 g × mol−1) and the
Avogadro constant so that 1 mole of an antibody contained
6.02 × 1023 antibody molecules.
In order to confirm successful conjugation of antibodies to
the nanoparticles we used the following approaches.
Anti-HMGB1 antibody-conjugated and naked (control)
AuNPs were exposed to HRP-conjugated streptavidin for
30 min followed by precipitation by centrifugation (16).
Nanomaterials were washed three times with bi-distilled water
and exposed for 2 min exposure to 6 mg/ml o-Phenylenediamine
(OPD) in the presence of hydrogen peroxide. The reaction was
stopped using 10% sulfuric acid. Nanomaterials were
precipitated by centrifugation (16) and the absorbance of
supernatants was analysed at 492 nm (Supplementary Figure 3).
Mouse anti-human TGF-b1-conjugated AuNPs were exposed
for 1 h to anti-mouse or anti-rabbit (control) fluorescent dye-
labelled Li-Cor secondary antibodies. nanomaterials were then
precipitated by centrifugation (16), washed three times with bi-
distilled water and analysed using Li-Cor Odyssey CLX imager
(Supplementary Figure 4).
Statistical Analysis
Each experiment was performed at least three times and
statistical analysis, when comparing two normally distributed
events at a time, was conducted using a two-tailed Student’s t-
test. In cases when multiple comparisons (more than two
groups) were performed, we used an ANOVA test. Post-hoc
Bonferroni correction was used where applicable. Statistical
probabilities (p) were expressed as * when p<0.05; **, p<0.01
and *** when p<0.001.RESULTS
Firstly, we investigated human monocytic AML THP-1 cells and
exposed them for 24 h to 1 μg/ml of immunogenic form of human
recombinant HMGB1 (6). We found that exposure to HMGB1
upregulated TGF-b secretion, which subsequently triggered
Smad3 phosphorylation (Figure 1A). This led to a substantial
increase in galectin-9 secretion and reduced levels of total cell-
associated and cell surface-based galectin-9 (Figures 1B, C).
Overall, an increase in total amounts of galectin-9 produced by
THP-1 cells was observed and also confirmed by measuring the
total quantities of galecting-9 present in cell lysates and secreted
protein in cell culture medium by ELISA. Resting cells produced
890 ± 48 pg/106 cells galectin-9 in total and this rose to 2110 ± 93June 2021 | Volume 12 | Article 675731
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galectin-9 expression suggests its proteolytic shedding off the cell
surface together with Tim-3 (which acts both as a receptor and
possible trafficker for galectin-9) (21). An increase in Tim-3
secretion was also observed (Figure 1D), which is known to be
governed by proteolytic shedding triggered by TLR4 signalling
(22). THP-1 cells express four HMGB1 receptors (6) – TLRs 2 and
4, receptor of advanced glycation end products (RAGE) and Tim-
3 (Supplementary Figure 5). To confirm the role of the TLRs 2
and 4 in observed responses we studied primary human AML cells
obtained from newly diagnosed patients. We selected patients
where AML cells expressed Tim-3 and RAGE, but did not express
(as determined by Western blotting) detectable amounts of TLRs
2 and 4 proteins, and exposed these AML cells to 2.5 μg/ml
HMGB1 for 16 h. None of the effects observed in THP-1 cells were
detected in these primary AML cells (Figure 2). These results
suggest that TLRs and not RAGE or Tim-3 are mediating
HMGB1-induced TGF-b secretion and follow-up events.
Interestingly, primary human AML cells expressing TLR4
responded to 16 h exposure to 2.5 μg/ml HMGB1 in a similar
manner to that observed for THP-1 cells – where the secretion of
both galectin-9 and Tim-3 was significantly upregulated
(Supplementary Figure 6).
To further investigate the differential roles of TLRs 2 and 4 in
the observed effects of HMGB1, we studied human colorectal
cancer cells (Colo 205), human breast cancer cells (MCF-7) and
human embryonic kidney cells (HEK293). Colo 205 expressed
TLR2, RAGE and Tim-3, whereas the other cell types
investigated expressed RAGE and Tim-3, but not the other
HMGB1 receptors – TLR4 and TLR2 (Supplementary
Figure 5). Of all the different cell types investigated,
upregulation of galectin-9 translocation onto the cell surface
was only observed in Colo 205 cells (these cells express TLR2)
upon exposure to 1 μg/ml HMGB1 for 24 h, but neither total
galectin-9 levels nor its secretion were upregulated in these cells
(Figure 3). Other effects which were observed in THP-1 cells, e.g.Frontiers in Immunology | www.frontiersin.org 4activation of TGF-b production, Smad-3 phosphorylation and
upregulated Tim-3 secretion, were undetectable in Colo 205 cells
(Figure 3). In other cell types – MCF-7 (Figure 4) and HEK293
(Figure 5) HMGB1 did not trigger any changes observed in
THP-1 cells. Taken together, these results suggest that TLR4
mediates HMGB1-induced TGF-b production followed by its
autocrine and paracrine effects.
We then tested if naturally occurring, dying cell-derived
HMGB1 can induce similar effects in TLR4 expressing cells.
We exposed several types of human cancer cell lines (THP-1,
Colo 205 and MCF-7) for 24 h to 100 μM BH3I-1 (5-[(4-
bromophenyl)methylene]-a-(1-methylethyl)-4-oxo-2-thioxo-3-
thiazolidineacetic acid), which is a synthetic cell-permeable Bcl-
XL antagonist that induces apoptosis (by inhibiting the
interactions between the BH3 domain and Bcl-XL thus
defunctionalising mitochondria) (23). We found that upon
stimulation with BH3I-1 THP-1 released the highest amounts
of HMGB1 (Supplementary Figure 7). To confirm the
physiological relevance of this observation, we compared
HMGB1 levels in the blood plasma of healthy donors, primary
breast cancer patients (a solid tumour where HMGB1 release was
assessed in breast cancer-derived MCF-7 cell lines) and AML
patients (a “liquid” tumour which was also tested using the THP-
1 cell line). We tested the blood plasma of 5 healthy donors, 5
AML patients and 5 patients with primary breast cancer. Here,
we observed that AML patients had significantly higher levels of
HMGB1 in their blood plasma compared to healthy donors and
primary breast cancer patients (Figure 6). These results suggest
that in the studied solid tumours HMGB1, if released, most likely
stays within the tumour microenvironment.
Given the results described above, THP-1 monocytic cells
were chosen to act as HMGB1 releasers and were exposed to 1
mM hydrogen peroxide for 24 h and released 13.14 ± 0.37 ng/ml
HMGB1 (Figure 7A). We used this medium (H2O2 was
degraded using 5 mg/ml horseradish peroxidase) to treat
THP-1 cells, which were pre-treated for 24 h with 100 nMA B DC
FIGURE 1 | HMGB1 induces TGF-b dependent expression of galectin-9 in THP-1 human AML cells. THP1 cells were exposed for 24 h to 1 µg/ml HMGB1 followed
by measurement of TGF-b secretion and Smad3 activating phosphorylation (A), galectin-9 protein expression and secretion (B), galectin-9 cell surface presence (C)
and Tim-3 protein expression and release (D). Images are from one experiment representative of 4 giving similar results. Quantitative data are shown as mean values
± SEM from 4 independent experiments. *p < 0.05 and **p < 0.01 vs control.June 2021 | Volume 12 | Article 675731
Teo Hansen Selnø et al. HMGB1 Induces Galectin-9 Expressionphorbol 12-myristate 13-acetate (PMA), in order to differentiate
them into macrophages which express high levels of TLR4
(24). As a control, we exposed PMA-pre-treated THP-1
cells to the same medium but depleted from HMGB1 by
immunoprecipitating HMGB1 using nanoconjugates (NCJ, 30
nm gold nanoparticles carrying antibodies against HMGB1) as
outlined in Materials in Methods. We found that HMGB1-
containing medium led to the production of ca. 15 ng/ml
TGF-b. This result suggests that naturally produced cell-
derived HMGB1 displays higher biological activity than the
recombinant protein. The effect was not observed in the cells
treated with medium where HMGB1 was removed (Figure 7A).
TGF-b-containing medium was then used to treat MCF-7
human breast cancer cells. As a control, we exposed MCF-7
cells to the same medium where TGF-b was immunoprecipitatedFrontiers in Immunology | www.frontiersin.org 5using NCJ (30 nm gold nanoparticles carrying antibody against
TGF-b) as described in Materials and Methods. We found that
TGF-b-containing medium significantly upregulated galectin-9
levels in MCF-7 cells (Figure 7A).
We then sought to further confirm the ability of the TLR4 to
mediate the observed effects. For this purpose we transfected
Colo 205 cells, where we could not detect TLR4 protein by
Western blot (Supplementary Figure 5), with constitutively
active TLR4 (mCD4-hTLR4, the construct which consists of
the human transmembrane and intracellular domains of TLR4
fused to the extracellular domain of mouse CD4, kindly provided
by Prof Ruslan Medzhitov, Yale University, USA) (18). The
presence of mCD4-hTLR4 resulted in the upregulation of
galectin-9 secretion and reduced its cell-associated levels. We
additionally measured cell-associated galectin-9 by ELISA andA B DC
FIGURE 2 | HMGB1 does not induce TGF-b secretion and galectin-9 expression in primary human AML cells lacking expressions of TLRs 2 and 4. Primary human
AML cells lacking expression of TLRs 2 and 4 were exposed for 16 h to 2.5 µg/ml HMGB1 and TGF-b secretion and Smad3 activating phosphorylation (A), galectin-
9 expression and secretion (B), expression of TLRs 2 and 4 as well as RAGE proteins (C) and Tim-3 protein expression and secretion (D) were analysed. Images are
from one experiment representative of 4 which gave similar results. Quantitative data are shown as mean values ± SEM from four independent experiments.A B DC
FIGURE 3 | The effects of HMGB1 on Galectin-9 and Tim-3 expression in Colo 205 human colorectal cancer cells. Colo 205 cells were exposed for 24 h to 1 µg/ml
HMGB1 followed by measurement of TGF-b secretion and Smad3 activating phosphorylation (A), galectin-9 protein expression and secretion (B), galectin-9 cell
surface presence (C) and Tim-3 protein expression and release (D). Images are from one experiment representative of four which gave similar results. Quantitative
data are expressed as mean values ± SEM of four independent experiments. **p < 0.01 vs control. N.D. in this and other figures denotes “not detectable”.June 2021 | Volume 12 | Article 675731
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Frontiers in Immunology | www.frontiersin.org 6observed that it was significantly downregulated in the cells
transfected with mCD4-hTLR4, while total galectin-9 levels
(secreted + cell-associated) were significantly upregulated in
mCD4-hTLR4-transfected cells (Figure 7B). Tim-3 secretion
of 95 ± 9 pg/106 cells was also observed in the presence of
mCD4-hTLR4 (Figure 7B) while in the cells which did not
contain mCD4-hTLR4 it was undetectable. Furthermore,
mCD4-hTLR4 upregulated TGF-b secretion, which led to the
upregulation of activating Smad3 phosphorylation in these
cells (Figure 7C).DISCUSSION
The role of HMGB1 as a “danger signal” or alarmin in cancer
progression has been extensively studied in the last decade (1–4,A B DC
FIGURE 4 | The effects of HMGB1 on Galectin-9 and Tim-3 expression in MCF-7 human breast cancer cells. MCF-7 cells were exposed for 24 h to 1 µg/ml
HMGB1 followed by measurement of TGF-b secretion and Smad3 activating phosphorylation (A), galectin-9 protein expression and secretion (B), galectin-9 cell
surface presence (C) and Tim-3 protein expression and release (D). Images are from one experiment representative of four which gave similar results. Quantitative
data are shown as mean values ± SEM of four independent experiments.A B DC
FIGURE 5 | The effects of HMGB1 on Galectin-9 and Tim-3 expression in HEK293 human embryonic kidney cells. MCF-7 cells were exposed for 24 h to 1 µg/ml
HMGB1 followed by measurement of TGF-b secretion and Smad3 activating phosphorylation (A), galectin-9 protein expression and secretion (B), galectin-9 cell
surface presence (C) and Tim-3 protein expression and release (D). Images are from one experiment representative of four which gave similar results. Quantitative
data are shown as mean values ± SEM of four independent experiments.FIGURE 6 | HMGB1 levels in blood plasma of human healthy donors and
cancer patients. HMGB1 levels were detected in blood plasma of 5 healthy
donors, 5 primary breast cancer (BC) patients, 5 metastatic breast cancer
patients and 5 AML patients. Data are mean values ± SEM of 5 independent
experiments. Individual values for each patient are shown as well. *p < 0.05
vs healthy donors.June 2021 | Volume 12 | Article 675731
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in anti-cancer immune evasion but the biochemical mechanisms
underlying this phenomenon remain unclear. In this work we
discovered that in cancer cells expressing TLR4, HMGB1 can
induce TGF-b production and secretion (Figure 1).
Interestingly, TLR4 has recently been shown to mediate TGF-b
production when activated by lipopolysaccharide (LPS), its
pathogen-associated ligand, and some endogenous stimuli such
as hyaluronic acid (25, 26). It was also demonstrated that
HMGB1-induced activation of TGF-b production in TLR4-
expressing cells takes place through the activator protein 1
(AP-1) transcription factor and its upstream pathway (9).
HMGB1 displays TLR4 ligand properties and could act in
TLR4-expressing cells similarly to that observed for LPS (6, 9).
An additional factor which could mediate HMGB1-induced
TGF-b expression in TLR4 expressing cells could be theFrontiers in Immunology | www.frontiersin.org 7hypoxia-inducible factor 1 (HIF-1) transcription complex,
which is upregulated by TLR4-mediated downstream signalling
(24). HIF-1 was shown to trigger the expression of TGF-b (9).
TGF-b secreted by TLR4-expressing cancer cells (in our case
THP-1 human AML cells), displays autocrine/paracrine
activities, and thus acts on the malignant cells which have
produced it. As a result, TGF-b induces galectin-9 production
by these cells in a Smad3-dependent manner, the effect which has
recently been reported (9) and confirmed in the present study.
Galectin-9 subsequently displays immunosuppressive activities
on cytotoxic and helper T cells in the tumour microenvironment
as well as on NK cells (10, 17). The effects of HMGB1-induced
galectin-9 expression were observed in the TLR4-expressing
THP-1 human AML cell line (Figure 1) as well as in primary
human AML cells expressing this receptor (Supplementary
Figure 6). Our further experiments demonstrated that if cellsA B
C
FIGURE 7 | TGF-b produced by TLR4 expressing cells upon stimulation with HMGB1 triggers galectin-9 expression in target cancer cells. Active TLR4 is capable of
inducing the same effects without HMGB1. (A) THP-1 cells were treated with 1 mM H2O2 for 24 h and the medium was collected for further use. This medium after
H2O2 degradation with or without immunoprecipitation of HMGB1 was used to treat PMA-differentiated THP-1 cells expressing high levels of TLR4 for 24 h. The
medium from PMA-treated THP-1 cells treated with HMGB1-containing medium was collected. This medium with or without immunoprecipitation of TGF-b was used
to incubate MCF-7 cells for 24 h followed by measurement of galectin-9 by Western blot. (B) Colo 205 cells were transfected with constitutively active TLR4 or
corresponding empty vector followed by 24h of incubation without further treatment. Expression of Tim-3 protein and it’s secretion (values are presented in the text),
galectin-9 protein expression by both Western blot and ELISA and secretion by ELISA were analysed. (C) TGF-b secretion and Smad3 activating phosphorylation
were also detected. Images are from one experiment representative of 4 giving similar results. Quantitative data are shown as mean values ± SEM from 4
independent experiments. *p < 0.05 and **p < 0.01 vs control.June 2021 | Volume 12 | Article 675731
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(TLR2, Tim-3 and RAGE), no induction of TGF-b secretion
takes place in these cells when exposed to HMGB1. This was the
case in primary human AML cells lacking TLR4 expression
(Figure 2), Colo 205 (Figure 3), MCF-7 (Figure 4) and
HEK293 cells (Figure 5) and, as a result, no subsequent
upregulation of galectin-9 expression was observed in
these cells. However, HMGB1 can still upregulate TGF-b
production in TLR4-expressing cells (e. g. tumour-associated
macrophages) present in the tumour microenvironment
where the released TGF-b may activate galectin-9 expression
in cancer cells. Furthermore, increased TGF-b in the
tumour microenvironment contributes to the creation of an
immunosuppressive milieu (27). TGF-b suppresses granzyme
B expressions in cytotoxic T cells, thus reducing their cell-
killing potential and impairing their anti-cancer activity
(28). Furthermore, TGF-b is known to contribute to the
differentiation of naïve T cells entering the tumour
microenvironment into regulatory T cells (Tregs) which
suppress the cytotoxic activities of T cells (29). This proposed
pathway is demonstrated using the example of a solid tumour
in Figure 8.
Taken together, our results suggest that HMGB1 potentially
plays a critical role in anti-cancer immune evasion and these
effects are facilitated by TLR4.DATA AVAILABILITY STATEMENT
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University, NHSFoundationTrust [MH363 (AM03) and 09/H0301/
37]. Written informed consent for participation was not required for
this study in accordance with the national legislation and the
institutional requirements.FIGURE 8 | Proposed mechanism of indirect upregulation of galectin-9 expression by HMGB1 in solid tumour cells lacking TLR4 expression is presented in
the scheme.June 2021 | Volume 12 | Article 675731
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